Navigation Links
BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
Date:3/8/2011

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking StatementsThis release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene -206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and will soon be available for sale in the United States.PR CONTACT:Matt RizzettaNorth 6th Agencymrizzetta@north6thagency.com 718-744-7138IR CONTACT:Jeff RamsonProActive Capital Resources Group, LLCjramson@proactivecrg.com 212-792-4294  FOR THE COMPANY:Stephen J. BrowandBioNeutral Group, Inc.steve@
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioNeutral Group to Receive Economic Development Incentives
2. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
4. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
6. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
9. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
10. Photonic Products Group, Inc. Announces New Sales and Marketing VP
11. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... to Focus on Specialty ... and Biotechnology, STAMFORD, Conn., April 21 Thomas, ... that invests in life science and,medical technology companies, today ... Entrepreneur-in-Residence in the firm,s Connecticut,office. Most recently, Dr. Tierney ...
... AB,(publ) has decided on, and successfully executed, a direct placement ... placed with a limited,group of professional investors at a price ... total for the Company before issue costs. For each,issued and ... which,gives the right to subscribe for a series B share ...
... and WINNERSH, England, April 21 Paul Capital,Healthcare ... they have,signed a financing agreement relating to frovatriptan, ... agreement, Vernalis will receive,approximately euro 18.4 million in ... Capital Healthcare will receive approximately 90 per cent,of ...
Cached Biology Technology:David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence 2Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 3
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... A team of Columbia University Medical Center (CUMC) ... found the first direct evidence of a link between ... hallmark of asthma. The study, conducted in mice, shows ... lung is forming can cause profound changes in the ...
... the subject of a symposium on Saturday, February 15, at the ... Science in Chicago. The session, which features two members of ... will take place 10:00-11:30 a.m. CST in Grand Ballroom B of ... 2014 winner of the Golden Goose Award will be ...
... Calif.) The rapid conversion of natural lands to cement-dominated ... to a new study involving 147 cities worldwide, surprisingly high ... in urban environments to the tune of hundreds of ... city. Contrary to conventional wisdom that cities are a ...
Cached Biology News:Prenatal vitamin A deficiency tied to postnatal asthma 2Prenatal vitamin A deficiency tied to postnatal asthma 3Cities support more native biodiversity than previously thought 2Cities support more native biodiversity than previously thought 3
... P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) mediate ... lumenal surface of endothelial cells at sites ... role of PSGL-1 in mediating the interaction ... documented.MAB4092 completely blocks recognition of PSGL-1 by ...
Request Info...
... of Printing Surface (3 glass slides coated with 100 ... silicon wafer coated with 1000 Angstroms of Gold over ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
LTBP-1 (E-20)...
Biology Products: